Elite in RUNX1 Familial Platelet Disorder

Torsten Haferlach

Munich, BY, DE 
Elite in RUNX1 Familial Platelet Disorder
Munich, BY, DE 
OverviewLocationsClinical Research

Overview

Torsten Haferlach practices in Munich, Germany. Mr. Haferlach is rated as an Elite expert by MediFind in the treatment of RUNX1 Familial Platelet Disorder. His top areas of expertise are Leukemia, Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), RUNX1 Familial Platelet Disorder, and Bone Marrow Transplant.

His clinical research consists of co-authoring 485 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 13 articles in the study of RUNX1 Familial Platelet Disorder.

Gender
Male

Locations

Munich, BY, Germany
Other Locations
Augsburg, BY, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

Treatment Optimization of Newly Diagnosed Ph/BCR-ABL Positive Patients With Chronic Myeloid Leukemia (CML) in Chronic Phase With Nilotinib vs. Nilotinib Plus Interferon Alpha Induction and Nilotinib or Interferon Alpha Maintenance Therapy
Treatment Optimization of Newly Diagnosed Ph/BCR-ABL Positive Patients With Chronic Myeloid Leukemia (CML) in Chronic Phase With Nilotinib vs. Nilotinib Plus Interferon Alpha Induction and Nilotinib or Interferon Alpha Maintenance Therapy
Enrollment Status: Completed
Publish Date: May 10, 2023
Intervention Type: Drug
Study Drugs: Peginterferon ?2b, Nilotinib
Study Phase: Phase 3

485 Total Publications

Distinct characteristics of VEXAS-causative UBA1 M41 and recurrent functional non-M41 mutations.
Distinct characteristics of VEXAS-causative UBA1 M41 and recurrent functional non-M41 mutations.
Journal: Leukemia
Published: August 22, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Haferlach's expertise for a condition
ConditionClose
View All 17 Distinguished Conditions
View All 17 Advanced Conditions
View All 31 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile